Reproducibility Study of OABSS and Its Response to Solifenacin Treatment (RESORT) and Validity in Korean Populations; Part 2: Responsiveness and Validity.
Latest Information Update: 12 Jul 2013
Price :
$35 *
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms RESORT-2
- Sponsors Astellas Pharma
- 11 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2011 New trial record